Fortress Biotech 2025 revenue rises, net loss narrows
Overview
U.S. biopharma firm's 2025 revenue rose yr/yr, with net loss narrowing sharply
Outlook
Fortress expects to receive at least $100 mln from Cyprium via future dividends and agreements
Company remains eligible for up to $4.8 mln CVR and 2.5% royalty on UNLOXCYT sales
Fortress could receive up to $128 mln in sales milestones and tiered royalties from ZYCUBO
Result Drivers
DERMATOLOGY PRODUCT SALES - Increased revenue from commercial launch and sales of Emrosi by Journey Medical
Company press release: ID:nGNX6ZZX4h
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
FY Revenue | Miss | $61.2 mln | $73.34 mln (2 Analysts) |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
Wall Street's median 12-month price target for Fortress Biotech Inc is $10.75, about 298.1% above its March 30 closing price of $2.70
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
